US3931397A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Biologically active material
Assignee: Beecham Group PLC
•
Filing: 1973-11-08
•
Granted: 1976-01-06
•
Expires: 1993-11-08
Abstract
Abstract This invention relates to antiviral substances, to a method for their preparation, and to pharmaceutical compositions comprising them.
Inventors
- 👤 Michael Raymond Harnden
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 14:55
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/74; A61K31/785
Claims Analysis
Total Claims: 6
Claim 1
Independent Claim
245 words
A pharmaceutical composition useful for treating viral infections caused by any one or more of a wide variety of DNA and RNA viruses in suseptible mammals which comprises an effective serum-interferon producing ribonuclease-stable amount of an antiviral complex which is a principally ionic complex soluble in 0.15 M aqueous sodium chloride solution in which the cations are organic polymer polycations having a plurality of quaternary nitrogen sites located at intervals along the polymer chains, said polycations having the formula ##EQU6## wherein each of a and b, independent of the other, is an integer of from 2 to 6 and X is a number which is such that the average molecular weight of the polycation divided by the equivalent weight which is the molecular weight of the polycation divided by the value (2X + 2) is not greater than 98, and the anions are one of: (a) double-stranded ribonucleic acid polyanions, said double-stranded ribonucleic acid being of natural origin, or (b) polyanions of a double-stranded ribonucleic acid of natural origin which has been subject to chemical or enzymatic reaction which alters one or more of the primary, secondary, and tertiary structure, provided that the resultant ribonucleic acid retains a substantial degree of base pairing between complementary strands, said antiviral complex having more than 60% of the anionic sites on the double-stranded ribonucleic acid anions neutralized by the quaternary cationic sites on the quaternary polymer, in combination with a pharmaceutically acceptable nontoxic liquid injectable or topical carrier.
Claim 2
Dependent Claim
245 words
A pharmaceutical composition useful for treating viral infections caused by any one or more of a wide variety of DNA and RNA viruses in suseptible mammals which comprises an effective serum-interferon producing ribonuclease-stable amount of an antiviral complex which is a principally ionic complex soluble in 0.15 M aqueous sodium chloride solution in which the cations are organic polymer polycations having a plurality of quaternary nitrogen sites located at intervals along the polymer chains, said polycations having the formula ##EQU6## wherein each of a and b, independent of the other, is an integer of from 2 to 6 and X is a number which is such that the average molecular weight of the polycation divided by the equivalent weight which is the molecular weight of the polycation divided by the value (2X + 2) is not greater than 98, and the anions are one of: (a) double-stranded ribonucleic acid polyanions, said double-stranded ribonucleic acid being of natural origin, or (b) polyanions of a double-stranded ribonucleic acid of natural origin which has been subject to chemical or enzymatic reaction which alters one or more of the primary, secondary, and tertiary structure, provided that the resultant ribonucleic acid retains a substantial degree of base pairing between complementary strands, said antiviral complex having more than 60% of the anionic sites on the double-stranded ribonucleic acid anions neutralized by the quaternary cationic sites on the quaternary polymer, in combination with a pharmaceutically acceptable nontoxic liquid injectable or topical carrier.
Claim 3
Dependent Claim
32 words
A pharmaceutical composition according to claim 1 wherein more than 75% of the anionic sites on the double-stranded ribonucleic acid anions are neutralized by the quaternary cationic sites on the quaternary polymer.
Claim 4
Dependent Claim
36 words
A pharmaceutical composition according to claim 1 wherein the double-stranded ribonucleic acid component is from the virus particles found in infected strains of Penicillium chrysogenum, Penicillium stoloniferum, Penicillium funiculosum, Penicillium cyaneofulvum, Aspergillus niger or Aspergillus foetidus.
Claim 5
Dependent Claim
11 words
A pharmaceutical composition according to claim 1 in injectable administration form.
Claim 6
Dependent Claim
21 words
A pharmaceutical composition according to claim 1 in a form suitable for application to the mucous membrane of a susceptible mammal.
References Cited (Backward Citations)
US3679654A
Cited
US3725545A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1979-01-05 | 1979-07-07 | 1980-01-06 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1983-01-05 | 1983-07-07 | 1984-01-06 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1987-01-05 | 1987-07-07 | 1988-01-06 | $7700.00 | Window Closed / Lapsed |